Positive News SentimentPositive NewsNASDAQ:PASG Passage Bio (PASG) Stock Price, News & Analysis $6.95 -0.05 (-0.71%) Closing price 09/15/2025 03:53 PM EasternExtended Trading$7.02 +0.07 (+0.99%) As of 09/15/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Passage Bio Stock (NASDAQ:PASG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Passage Bio alerts:Sign Up Key Stats Today's Range$6.82▼$7.1350-Day Range$5.27▼$8.8252-Week Range$5.12▼$26.60Volume41,417 shsAverage Volume32,439 shsMarket Capitalization$22.09 millionP/E RatioN/ADividend YieldN/APrice Target$75.67Consensus RatingBuy Company Overview Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration. The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit. Passage Bio is also advancing PBFT02, an AAV-based gene therapy targeting progranulin deficiency in frontotemporal dementia linked to GRN mutations, and PBCH10 for achromatopsia, a rare inherited form of color blindness. Each program is designed to address significant unmet needs in genetically defined patient populations. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Passage Bio emerged from collaborations with academic and research institutions specializing in gene therapy and neurology. The company completed its initial public offering in 2020 to support clinical development and expand manufacturing capabilities. Its leadership team is led by President and Chief Executive Officer David Meeker, who brings extensive experience in biotechnology and rare disease drug development. Passage Bio conducts its clinical and preclinical activities primarily in the United States and collaborates with international research centers to facilitate patient access and data collection. The company is committed to advancing transformational therapies for patients with severe genetic disorders and strengthening its vector manufacturing infrastructure to ensure scalable and compliant production.AI Generated. May Contain Errors. Read More Passage Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScorePASG MarketRank™: Passage Bio scored higher than 82% of companies evaluated by MarketBeat, and ranked 212th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialPassage Bio has a consensus price target of $75.67, representing about 988.7% upside from its current price of $6.95.Amount of Analyst CoveragePassage Bio has only been the subject of 3 research reports in the past 90 days.Read more about Passage Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($1.03) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Passage Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.81% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently decreased by 13.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.81% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently decreased by 13.90%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment1.89 News SentimentPassage Bio has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Passage Bio this week, compared to 1 article on an average week.Search Interest8 people have searched for PASG on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have bought 385.41% more of their company's stock than they have sold. Specifically, they have bought $957,384.00 in company stock and sold $197,233.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Passage Bio is held by insiders.Percentage Held by Institutions53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Passage Bio's insider trading history. Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PASG Stock News HeadlinesPassage Bio (NASDAQ:PASG) Raised to Hold at Wall Street ZenSeptember 7, 2025 | americanbankingnews.comPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Passage Bio (PASG) Receives a Buy from TD CowenAugust 15, 2025 | theglobeandmail.comPassage Bio price target lowered to $67 from $260 at CanaccordAugust 14, 2025 | msn.comPassage Bio Reports Q2 2025 Progress and FinancialsAugust 13, 2025 | msn.comPassage Bio reports Q2 EPS ($2.96) vs ($5.09) last yearAugust 12, 2025 | msn.comPassage Bio Reports Promising Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSee More Headlines PASG Stock Analysis - Frequently Asked Questions How have PASG shares performed this year? Passage Bio's stock was trading at $11.3420 at the beginning of the year. Since then, PASG shares have decreased by 38.7% and is now trading at $6.95. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) released its earnings results on Tuesday, August, 12th. The company reported ($2.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.00) by $1.04. When did Passage Bio's stock split? Passage Bio shares reverse split before market open on Monday, July 14th 2025.The 1-20 reverse split was announced on Thursday, July 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an initial public offering on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager. Who are Passage Bio's major shareholders? Top institutional investors of Passage Bio include Orbimed Advisors LLC (194.08%), Geode Capital Management LLC (17.26%), Bridgeway Capital Management LLC (13.08%) and Simplex Trading LLC. Insiders that own company stock include Lynx1 Capital Management Lp, Orbimed Advisors Llc, Mark S Forman, Alexandros Fotopoulos, Kathleen Borthwick and Simona King. View institutional ownership trends. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Enovix (ENVX), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST), Globant (GLOB) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/12/2025Today9/15/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PASG CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Price Target for Passage Bio$75.67 High Price Target$120.00 Low Price Target$40.00 Potential Upside/Downside+988.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($18.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$64.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-103.87% Return on Assets-59.95% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.84 per share Price / Book0.35Miscellaneous Outstanding Shares3,179,000Free Float3,042,000Market Cap$22.09 million OptionableOptionable Beta1.82 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PASG) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.